Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 82

Results For "therapies"

1238 News Found

Moderna and CytomX partner for mRNA-based conditnionally activated therapeutics
News | January 11, 2023

Moderna and CytomX partner for mRNA-based conditnionally activated therapeutics

Collaboration to generate and develop therapeutics for oncology and non-oncology conditions


Applied Therapeutics partners with Advanz Pharma for commercialization of Govorestat in Europe
Biotech | January 05, 2023

Applied Therapeutics partners with Advanz Pharma for commercialization of Govorestat in Europe

Advanz Pharma will leverage its specialty, hospital, and rare disease expertise and infrastructure to commercialize AT-007 in Europe for both Galactosemia and SORD Deficiency


CNS Pharmaceuticals appoints Faith L. Charles as Chair of the Board of Directors
People | January 04, 2023

CNS Pharmaceuticals appoints Faith L. Charles as Chair of the Board of Directors

Over 30 years of deep life sciences industry experience with a wide range of expertise in corporate governance, capital markets, licensing and strategic collaborations


Polysciences announces new bioprocessing brand ‘Kyfora Bio’
News | January 03, 2023

Polysciences announces new bioprocessing brand ‘Kyfora Bio’

Kyfora Bio will focus on the synthesis of cationic polymers, lipids, and other materials used in nucleic acid delivery for cell and gene therapies.


USFDA grants appeal for Ardelyx's XPHOZAH
Drug Approval | December 31, 2022

USFDA grants appeal for Ardelyx's XPHOZAH

Upon approval, XPHOZAH would be the first and only phosphate absorption inhibitor, offering patients a novel mechanism


Cipla EU to invest € 15 million in Ethris
News | December 30, 2022

Cipla EU to invest € 15 million in Ethris

Cipla and Ethris partner for the development of mRNA-based therapies


Lynparza in combination with Abiraterone and Prednisone approved in the EU as treatment for metastatic castration-resistant prostate cancer
Clinical Trials | December 22, 2022

Lynparza in combination with Abiraterone and Prednisone approved in the EU as treatment for metastatic castration-resistant prostate cancer

First PARP inhibitor and new hormonal agent combination approved for these patients in Europe


Diabetic neuropathic pain field presents significant opportunity for drug developers, says GlobalData
Healthcare | December 20, 2022

Diabetic neuropathic pain field presents significant opportunity for drug developers, says GlobalData

36.4% of patients with diabetic neuropathic pain in 2021 were completely treatment refractory and would benefit from new treatment options.